Brief: Pardes Biosciences Presents Interim Clinical Data From Ongoing PBI-0451 Phase 1 Trial
14/02/2022 14:06
Feb 14 (Reuters) - Pardes Biosciences Inc PRDS.O :
* PARDES BIOSCIENCES PRESENTS INTERIM CLINICAL DATA FROM
ONGOING
PBI-0451 PHASE 1 TRIAL SUPPORTING THE POTENTIAL OF PBI-0451 AS A
STAND-ALONE ORAL REGIMEN FOR COVID-19 AT CONFERENCE ON
RETROVIRUSES AND OPPORTUNISTIC INFECTIONS 2022
* PARDES BIOSCIENCES INC - PBI-0451 HAS BEEN GENERALLY
WELL-TOLERATED AND HAS SHOWN GOOD ORAL BIOAVAILABILITY
* PARDES - PBI-0451 ADMINISTERED TWICE-DAILY AGENT ACHIEVES,
MAINTAINS PK EXPOSURES ANTICIPATED TO PROVIDE POTENT ANTIVIRAL
ACTIVITY AGAINST SARS-COV-2
Source text for Eikon: ID:
Further company coverage: PRDS.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Pardes Biosciences
See all newsBrief: Pardes Biosciences Inc - Total Cash Amount That Medipacific Sub, Inc. Will Pay Pursuant To Terms Of Offer And Merger Agreement Is $2.13 Per Share
U.S. STOCKS ON THE MOVE-Argenx, ViewRay, Ford
Pardes Biosciences up on buyout deal with MediPacific
U.S. STOCKS ON THE MOVE-Activision Blizzard, Tesla, Paramount Global
Pardes Biosciences gains on buyout deal with MediPacific